Nora M Navone

Nora M Navone

UNVERIFIED PROFILE

Are you Nora M Navone?   Register this Author

Register author
Nora M Navone

Nora M Navone

Publications by authors named "Nora M Navone"

Are you Nora M Navone?   Register this Author

50Publications

1261Reads

25Profile Views

Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.

Oncogene 2019 04 7;38(14):2451-2463. Epub 2018 Dec 7.

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-018-0606-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450769PMC
April 2019

FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.

Urol Oncol 2018 08 7;36(8):365.e15-365.e26. Epub 2018 Jun 7.

Molecular Urooncology, Department of Urology, Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany; Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.05.020DOI Listing
August 2018

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Mol Cancer Res 2016 04 20;14(4):324-31. Epub 2016 Jan 20.

Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan. Department of Pathology, University of Michigan, Ann Arbor, Michigan. Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan. Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan. Department of Urology, University of Michigan, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-15-0472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834259PMC
April 2016

Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.

Epigenetics 2016 03 18;11(3):184-93. Epub 2016 Feb 18.

f Department of Genitourinary Medical Oncology , Unit 1374, The University of Texas MD Anderson Cancer Center , 1515 Holcombe Blvd., Houston , Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15592294.2016.1146851DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854553PMC
March 2016

A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.

Biomaterials 2016 Jan 9;77:164-72. Epub 2015 Nov 9.

Department of Bioengineering, Rice University, 6500 Main Street, Houston, TX 77030, USA; Department of Genitourinary Medical Oncology and the David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of BioSciences, Rice University, 6500 Main Street, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2015.10.059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684431PMC
January 2016

Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.

Oncotarget 2015 Oct;6(33):34329-41

Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.6020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741456PMC
October 2015

PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

Proc Natl Acad Sci U S A 2015 Jul 15;112(27):8403-8. Epub 2015 Jun 15.

David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030; University of New Mexico Cancer Center, University of New Mexico School of Medicine, Albuquerque, NM 87131; Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131; Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030; Division of Hematology/Oncology, University of New Mexico School of Medicine, Albuquerque, NM 87131;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1507882112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500257PMC
July 2015

Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.

Proc Natl Acad Sci U S A 2015 Mar 11;112(12):3776-81. Epub 2015 Mar 11.

University of New Mexico Cancer Center and Hematology and Oncology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131; and

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1500128112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378428PMC
March 2015

Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening.

Mol Pharm 2014 Jul 29;11(7):2040-50. Epub 2014 Apr 29.

Departments of Biochemistry and Cell Biology and ‡Bioengineering, Rice University , Houston, Texas 77005, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/mp500085pDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096229PMC
July 2014

Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.

Prostate 2012 Nov 27;72(15):1638-47. Epub 2012 Mar 27.

Department of Genitourinary Medical Oncology, The David Koch Center for Applied Research of Genitourinary Cancers, The Stanford Alexander Tissue Derivatives Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.22517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977841PMC
November 2012

Arachidonic acid metabolism in human prostate cancer.

Int J Oncol 2012 Oct 10;41(4):1495-503. Epub 2012 Aug 10.

Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2012.1588DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982713PMC
October 2012

Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.

PLoS One 2011 14;6(12):e28840. Epub 2011 Dec 14.

Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0028840PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237548PMC
August 2012

Vascular patterning and permeability in prostate cancer models with differing osteogenic properties.

NMR Biomed 2012 Jun 2;25(6):843-51. Epub 2011 Dec 2.

Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/nbm.1800
Publisher Site
http://dx.doi.org/10.1002/nbm.1800DOI Listing
June 2012

Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.

Bone 2012 Mar 7;50(3):695-703. Epub 2011 Dec 7.

Department of Genitourinary Medical Oncology-Research, Unit 18-6, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2011.11.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278589PMC
March 2012

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

Clin Cancer Res 2012 Feb 12;18(3):666-77. Epub 2011 Dec 12.

Department of Genitourinary Medical Oncology, Stanford Alexander Tissue Derivatives Laboratory, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-1867DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923417PMC
February 2012

Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Clin Cancer Res 2012 Feb;18(3):726-36

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2521DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271798PMC
February 2012

Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Clin Cancer Res 2011 Apr 22;17(8):2328-38. Epub 2011 Feb 22.

Department of Experimental Therapeutics and Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2943DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078947PMC
April 2011

TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

Hum Pathol 2011 Jan 30;42(1):11-7. Epub 2010 Oct 30.

Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2010.05.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972369PMC
January 2011

Adipose tissue-derived stem cells promote prostate tumor growth.

Prostate 2010 Nov;70(15):1709-15

Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.21206DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977846PMC
November 2010

Prioritizing genes associated with prostate cancer development.

BMC Cancer 2010 Nov 2;10:599. Epub 2010 Nov 2.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-10-599DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988752PMC
November 2010

P-TEFb joins the family of cdks in oncology, promotes cell growth of cancer cells.

Authors:
Nora M Navone

Cell Cycle 2010 Aug 1;9(15):2935. Epub 2010 Aug 1.

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/cc.9.15.12738
Publisher Site
http://dx.doi.org/10.4161/cc.9.15.12738DOI Listing
August 2010

Androgen depletion up-regulates cadherin-11 expression in prostate cancer.

J Pathol 2010 May;221(1):68-76

Department of Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.2687DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936767PMC
May 2010

Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.

Clin Cancer Res 2008 Jun;14(12):3729-36

Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-0472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2562877PMC
June 2008

Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.

Clin Cancer Res 2008 Mar;14(6):1599-602

Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-07-4603DOI Listing
March 2008

A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells.

Cancer Res 2007 Jul;67(14):6544-8

Department of Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-1330DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000837PMC
July 2007

In vivo imaging of prostate cancer involving bone in a mouse model.

Prostate 2007 Jan;67(1):50-60

Department of Radiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.20494DOI Listing
January 2007

Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.

Cancer Res 2006 Nov;66(22):10919-28

Department of Experimental Therapeutics and Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-0459DOI Listing
November 2006

Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1alpha-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3.

J Steroid Biochem Mol Biol 2005 Oct 2;97(1-2):203-11. Epub 2005 Aug 2.

Department of Endocrine Neoplasia and Hormonal Disorders, Unit 435, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsbmb.2005.06.015DOI Listing
October 2005

[Preclinical models of prostate cancer].

Bull Cancer 2005 Feb;92(2):129-41

Institut Gustave-Roussy, Département de médecine, 39, rue Camille-Desmoulins, 94800 Villejuif, France.

View Article

Download full-text PDF

Source
February 2005

High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.

Anticancer Res 2004 Sep-Oct;24(5A):2897-903

Department of Medicine, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
December 2004

Isolation and culture of prostate cancer cell lines.

Methods Mol Med 2004 ;88:121-32

Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
March 2004

p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells.

Carcinogenesis 2002 Aug;23(8):1289-96

Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/23.8.1289DOI Listing
August 2002

The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.

Clin Cancer Res 2002 Mar;8(3):775-81

Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
March 2002

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.

Cancer Lett 2002 Feb;176(1):57-63

Endocrine, Polypeptide and Cancer Institute, Veterans Administration Medical Center, 1601 Perdido Street, New Orleans, LA 70146, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0304-3835(01)00734-0DOI Listing
February 2002